MoonLake Immunotherapeutics (NASDAQ:MLTX) shares are up during Monday’s premarket session following the announcement of positive topline results from its Phase 2 clinical trial of sonelokimab in treating axial spondyloarthritis.Axial Spondyloarthritis is a chronic, immune-mediated inflammatory disease mainly affecting the spine and sacroiliac joints, often causing chronic back pain, stiffness, and potential spinal fusion.Chronic Back Pain StudyIn the Phase 2 S-OLARIS trial, 81% of patients treated with sonelokimab achieved a clinically meaningful response at Week 12, demonstrating significant improvement in key disease parameters.The trial also confirmed the drug’s ability to reduce inflammation and osteoblast activity in affected joints, suggesting a rapid onset of action and potential for effective treatment in chronic rheumatological conditions.As a biomarker-controlled trial, S-OLARIS data showed sonelokimab reduced the levels of key inflammatory mediators in axial spondyloarthritis, in peripheral blood and biopsy samples from patients – the safety profile of sonelokimab was similar to other trials ...Full story available on Benzinga.com
MoonLake Immunotherapeutics Data Shows Phase 2 Success For Chronic Back Pain
